About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a company based in Carlsbad (United States) founded in 1990. It operates as a HealthTech. Lineage Cell Therapeutics has raised $45.8 million across 22 funding rounds from investors including Juvenescence, State of California and HHS. The company has 77 employees as of December 31, 2024. Lineage Cell Therapeutics has completed 4 acquisitions, including Asterias Biotherapeutics, Canadian Neighbor Pharmacy and Glycosan. Lineage Cell Therapeutics offers products and services including OpRegen and OPC1. Lineage Cell Therapeutics operates in a competitive market with competitors including Revance Therapeutics, Dermavant, Remegen, Sol-Gel Technologies and SkinMedica, among others.
- Headquarter Carlsbad, United States
- Employees 77 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lineage Cell Therapeutics, Inc.
-
Annual Revenue
$9.5 M (USD)6.19as on Dec 31, 2024
-
Net Profit
-$18.61 M (USD)13.39as on Dec 31, 2024
-
EBITDA
-$20.87 M (USD)13.19as on Dec 31, 2024
-
Total Equity Funding
$45.8 M (USD)
in 22 rounds
-
Latest Funding Round
Not available
-
Investors
Juvenescence
& 3 more
-
Employee Count
77
as on Dec 31, 2024
-
Investments & Acquisitions
Asterias Biotherapeutics
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lineage Cell Therapeutics
Lineage Cell Therapeutics is a publicly listed company on the AMEX with ticker symbol LCTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lineage Cell Therapeutics
Lineage Cell Therapeutics offers a comprehensive portfolio of products and services, including OpRegen and OPC1.
Cell therapy developed for dry AMD treatment in patients.
Cell therapy designed for spinal cord injury recovery.
Funding Insights of Lineage Cell Therapeutics
Lineage Cell Therapeutics has successfully raised a total of $45.8M across 22 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lineage Cell Therapeutics
Lineage Cell Therapeutics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Juvenescence, State of California and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Access to government programs and development services is provided.
|
Locked | Locked | Locked | |
|
Business development in Israel is supported by a government organization.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Lineage Cell Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lineage Cell Therapeutics
Lineage Cell Therapeutics has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Asterias Biotherapeutics, Canadian Neighbor Pharmacy and Glycosan.
Investment portfolio details for Lineage Cell Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of cell therapy programs to treat cancer and neurological diseases
|
Locked | Locked | 2013 | Locked | |
|
Canadian Neighbor Pharmacy is engaged in online distribution of generic medications.
|
Locked | Locked | 2012 | Locked | |
|
Biocompatible hydrogels mimicking extracellular matrix are developed for tissue engineering.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Lineage Cell Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lineage Cell Therapeutics
Detailed financials for Lineage Cell Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lineage Cell Therapeutics Comparisons
Peer comparison for Lineage Cell Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lineage Cell Therapeutics
Lineage Cell Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, Remegen, Sol-Gel Technologies and SkinMedica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Skin care products are developed and manufactured by SkinMedica.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Detailed competitors of Lineage Cell Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lineage Cell Therapeutics
Complete news archive for Lineage Cell Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lineage Cell Therapeutics
Lineage Cell Therapeutics was founded in 1990 and raised its 1st funding round 19 years after it was founded.
Lineage Cell Therapeutics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Brian Culley is the current CEO of Lineage Cell Therapeutics.
Lineage Cell Therapeutics is a funded company, having raised a total of $45.8M across 22 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Lineage Cell Therapeutics is 77.
Annual revenue of Lineage Cell Therapeutics is $9.5M as on Dec 31, 2024.
Lineage Cell Therapeutics is engaged in the development of novel allogeneic cell therapies targeting serious neurological and ophthalmic conditions. The company utilizes a proprietary cell-based technology platform for designing, manufacturing, and testing specialized human cells. These cells are intended to replace or support dysfunctional cells caused by degenerative diseases, aging, or traumatic injuries. Programs such as OpRegen for dry AMD and OPC1 for spinal cord injury are advanced internally or with strategic partners like Genentech to enhance therapeutic value and success probability in the healthcare sector.
Lineage Cell Therapeutics's top competitors include Revance Therapeutics, Remegen and Dermavant.
Lineage Cell Therapeutics offers OpRegen and OPC1.
Yes, Lineage Cell Therapeutics is publicly traded on AMEX under the ticker symbol LCTX.
Lineage Cell Therapeutics has made 4 acquisitions, including Asterias Biotherapeutics, Canadian Neighbor Pharmacy, and Glycosan.
Lineage Cell Therapeutics has 4 investors. Key investors include Juvenescence, State of California, HHS, and Israel Innovation Authority.
The ticker symbol of Lineage Cell Therapeutics is LCTX on AMEX.